Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Orion Oyj Share Issue/Capital Change 2015

Sep 24, 2015

3232_rns_2015-09-24_5eef1a79-6b92-4fa1-9d35-02baaa6bd2c5.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Disclosure 327113

Orion - Company Announcement

234,620 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE 24 SEPTEMBER 2015 at 9.45 a.m. EEST 234,620 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 234,620 A shares have been converted into 234,620 B shares. The conversion has been entered into the Trade Register on 24 September 2015. The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 39,191,154 A shares and 102,066,674 B shares. Orion Corporation Olli Huotari Jari Karlson SVP, Corporate Functions CFO Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki. [HUG#1954217]